DSM-Firmenich AG/€DSFIR

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About DSM-Firmenich AG

DSM-Firmenich AG, established in May 2023 through the merger of Dutch company DSM N.V. and Swiss company Firmenich SA, operates in the nutrition, health, and beauty industries. The company is organized into four segments: Perfumery & Beauty, offering fragrance solutions; Taste, Texture & Health, providing food and beverage ingredients; Health, Nutrition & Care, delivering dietary supplements and medical nutrition products; and Animal Nutrition & Health, supplying animal feed ingredients. Headquartered in Kaiseraugst, Switzerland, and Maastricht, Netherlands, DSM-Firmenich has operations in nearly 60 countries and employs approximately 30,000 people. The merger combines DSM's expertise in health and nutrition with Firmenich's capabilities in perfumery and taste, positioning the company to offer integrated solutions across its sectors. (,)

Ticker

€DSFIR
Sector

Primary listing

AEX

Industry

Chemicals

Headquarters

Kaiseraugst, Switzerland

Employees

26,301

ISIN

CH1216478797

DSM-Firmenich AG Metrics

BasicAdvanced
€24B
96.53
€0.94
-
€2.50
1.17%

Bulls say / Bears say

DSM-Firmenich's strategic divestment of its stake in the Feed Enzyme alliance for approximately €1.5 billion strengthens its balance sheet and aligns with its focus on core businesses, potentially enhancing shareholder value. (Investing.com)
The company's announcement of a share buyback program up to €1 billion demonstrates confidence in its financial health and commitment to returning value to shareholders. (TradingView News)
DSM-Firmenich's adjusted EBITDA margin improved to 19.9% in Q1 2025, indicating enhanced operational efficiency and profitability. (TradingView News)
A U.S. federal judge ruled that DSM-Firmenich must face lawsuits alleging price-fixing in the fragrance industry, which could lead to financial penalties and reputational damage. (Reuters)
The company reported Q1 2025 adjusted core profit slightly below market expectations, which may raise concerns about its short-term financial performance. (TradingView News)
DSM-Firmenich is working to mitigate the impact of U.S. tariffs on its business, but these trade barriers could still affect profitability and market competitiveness. (TradingView News)
Data summarised monthly by Lightyear AI. Last updated on 3 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €DSFIR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs